Amarantus BioScience (AMBS) 10-Q 20 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	20-May-14
Document Information [Line Items]	'	'
Entity Registrant Name	'Amarantus Bioscience Holdings, Inc.	'
Entity Central Index Key	'0001424812	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'AMBSE	'
Entity Common Stock, Shares Outstanding	'	732,042,008
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$3,765	$1,033
Clinical trial material	500	0
Deferred funding fees, net	129	109
Prepaid expenses and other current assets	131	106
Total current assets	4,525	1,248
Property and equipment, net	8	0
Intangibles, net	1,338	611
Total assets	5,871	1,859
Current liabilities:	'	'
Accounts payable (includes related parties $438 and $490 as of March 31, 2014 and December 31, 2013, respectively)	1,744	972
Related party liabilities and accrued interest	249	248
Accrued expenses	223	292
Accrued interest	56	112
Demand promissory note	500	0
8% Senior convertible debentures, net of discount	178	932
Convertible promissory notes	114	124
Derivative liability	409	5,859
Total current liabilities	3,473	8,539
Total liabilities	3,473	8,539
Commitments and contingencies	'	'
Stockholders’ equity (deficit)	'	'
Common stock, $0.001 par value — 1,000,000,000 shares authorized; 729,680,790 and 574,171,945 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	730	574
Additional paid-in capital	33,428	18,938
Accumulated deficit	-32,600	-27,032
Total stockholders' equity (deficit)	1,559	-7,519
Total liabilities and stockholders' equity (deficit)	5,871	1,859
Series A Convertible Preferred Stock [Member]	'	'
Stockholders’ equity (deficit)	'	'
Preferred Stock, Value, Issued	0	0
Series B Convertible Preferred Stock [Member]	'	'
Stockholders’ equity (deficit)	'	'
Preferred Stock, Value, Issued	0	0
Series C Convertible Preferred Stock [Member]	'	'
Stockholders’ equity (deficit)	'	'
Preferred Stock, Value, Issued	1	1
Series D Convertible Preferred Stock [Member]	'	'
Stockholders’ equity (deficit)	'	'
Preferred Stock, Value, Issued	$839	$839

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts Payable, Related Parties, Current	$438	$490
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares Issued	729,680,790	574,171,945
Common Stock, Shares Outstanding	729,680,790	574,171,945
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Series D Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$1,000	$1,000
Preferred Stock Shares, Designated	1,300	1,300
Preferred Stock, Shares Issued	1,299,327	1,299,327
Preferred Stock, Shares Outstanding	1,299,327	1,299,327
Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Series A Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock Shares, Designated	250,000	250,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series B Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock Shares, Designated	3,000,000	3,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series C Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock Shares, Designated	750,000	750,000
Preferred Stock, Shares Issued	750,000	750,000
Preferred Stock, Shares Outstanding	750,000	750,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		75 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Net sales	$0	$0	$416
Operating expense:	'	'	'
Research and development	517	664	4,796
General and administrative	1,119	1,221	12,692
Total operating expenses	1,636	1,885	17,488
Loss from operations	-1,636	-1,885	-17,072
Other income (expense):	'	'	'
Interest expense	-638	-873	-5,998
Loss on issuance of common stock	-67	0	-419
Loss on issuance of warrants	-3,867	0	-3,867
Loss on issuance of debt	0	0	-6,709
Other income (expense)	0	0	76
Change in fair value of warrants and derivative liabilities	666	-1,880	1,820
Total other income (expense)	-3,906	-2,753	-15,097
Net loss	-5,542	-4,638	-32,169
Preferred stock dividend	26	0	64
Net loss applicable to common shareholders	($5,568)	($4,638)	($32,233)
Basic and diluted net loss per common share (in dollars per share)	($0.01)	($0.01)	'
Basic and diluted weighted average common shares outstanding (in shares)	630,720,618	368,215,835	'

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
In Thousands, except Share data
Balances at Dec. 31, 2013	($7,519)	$1	$574	$18,938	($27,032)
Balances (in shares) at Dec. 31, 2013	'	750,000	574,171,945	'	'
Common stock issued for services	184	0	2	182	0
Common stock issued for services (in shares)	'	0	2,500,000	'	'
Common stock issued for license	228	0	4	224	0
Common stock issued for license (in shares)	'	0	3,641,002	'	'
Common stock sold	400	0	4	396	0
Common stock sold (in shares)	'	0	4,000,000	'	'
Deferred funding costs charged to equity upon sale of common stock	-400	0	0	-400	0
Common stock issued for funding fees	516	0	6	510	0
Common stock issued for funding fees (in shares)	'	0	6,000,000	'	'
Common stock issued upon conversion of 8% senior convertible debentures	3,091	0	78	3,013	0
Common stock issued upon conversion of 8% senior convertible debentures (in shares)	'	0	77,405,866	'	'
Common stock issued in settlement of notes payable	11	0	1	10	0
Common stock issued in settlement of notes payable (in shares)	'	0	1,095,759	'	'
Common stock issued for Series D convertible preferred stock dividend	26	0	1	25	0
Common stock issued for Series D convertible preferred stock dividend (in shares)	'	0	866,218	'	'
Loss on issuance of common stock	67	0	0	67	0
Common stock issued upon exercise of common stock warrants	3,600	0	60	3,540	0
Common stock issued upon exercise of common stock warrants (in shares)	'	0	60,000,000	'	'
Deferred funding costs charged to equity upon exercise of warrants	-190	0	0	-190	0
Loss on issuance of warrants	3,867	0	0	3,867	0
8% senior convertible debentures converted and associated reclassification of derivative liability	3,044	'	0	3,044	0
Series D convertible preferred stock 8% dividend accrued at period end	-26	'	0	0	-26
Stock-based compensation expense	202	0	0	202	0
Net loss	-5,542	0	0	0	-5,542
Balances at Mar. 31, 2014	$1,559	$1	$730	$33,428	($32,600)
Balances (in shares) at Mar. 31, 2014	'	750,000	729,680,790	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		75 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash flows from operating activities	'	'	'
Net loss	($5,542)	($4,638)	($32,169)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation and amortization	1	0	34
Amortization of debt discount	500	476	2,924
Amortization of deferred financing fees	96	0	362
Amortization of intangibles	24	0	94
Stock issued for services	184	293	2,682
Loss on debt issuance	0	0	6,709
Loss on stock issuance	67	0	1,092
Loss on warrant issuance	3,867	0	3,867
Gain on disposal of equipment	0	0	-3
Preferred stock Series C issued as compensation	0	0	39
Non-cash interest expense related to warrants and derivative	32	0	796
Common stock issued at conversion of Series A preferred stock	0	0	127
Gain on settlement of convertible note and warrants	0	0	-138
Change in fair value of warrants and derivative liability	-666	1,881	-1,815
Stock-based compensation expense	202	508	2,011
Changes in assets and liabilities:	'	'	'
Related party liabilities and accrued interest	1	0	-139
Clinical trial material	-500	0	-500
Prepaid expenses and other current assets	-25	202	-159
Accounts payable	560	257	4,038
Accrued liabilities and accrued interest	-60	81	683
Net cash used in operating activities	-1,259	-940	-9,465
Cash flows from investing activities	'	'	'
Acquisition of property and equipment	-9	0	-49
Acquisition of other assets	-500	-35	-625
Security deposit write-off	0	1	-1
Net cash used by investing activities	-509	-34	-675
Cash flows from financing activities	'	'	'
Proceeds from borrowings	500	1,200	8,219
Repayment of borrowings	0	-143	-451
Proceeds from issuance of common stock	400	0	2,198
Proceeds from exercise of warrants	3,600	0	3,600
Proceeds from issuance of stock options	0	0	201
Proceeds from issuance of convertible preferred stock	0	0	540
Net cash provided by financing activities	4,500	1,057	13,905
Net increase in cash and cash equivalents	2,732	83	3,765
Cash and cash equivalents Beginning of period	1,033	157	0
Cash and cash equivalents End of period	3,765	240	3,765
Supplemental schedule of non-cash activities:	'	'	'
Bifurcation of derivatives embedded in convertible notes	0	0	548
Beneficial conversion feature - Series D convertible preferred stock	0	0	321
Beneficial conversion feature - debt discount - convertible promissory notes	0	0	226
Relative fair value associated with senior secured convertible debentures issued with detachable warrants	0	0	1,939
Convertible promissory notes converted and associated reclassification of derivative liability	0	0	2,712
Convertible debentures converted and associated reclassification of derivative liabilities	7,778	0	7,778
Debt discount written off - associated with convertible promissory notes	-1,740	0	-1,990
Debt discount associated with convertible promissory notes - derivative liability	0	0	813
Stock warrants reclassified from liabilities to equity	0	0	39
Preferred stock issued in lieu of payment of payable	0	250	250
Preferred stock Series D issued for accounts payable	0	0	1,169
Convertible promissory notes issued for payables and accrued liabilities	0	15	653
Convertible notes payable issued for accounts payables	0	0	162
Issuance of warrants to investors	0	0	371
Stock issued for deferred funding fees	516	0	547
Payables forgiven for property and equipment	0	0	10
Stock issued to acquire intangible assets	0	79	556
Stock issued to satisfy accounts payable and accrued expenses	0	527	820
Stock issued for notes payable	0	0	2,200
Stock issued for convertible debt	11	538	2,435
Intrinsic value of beneficial conversion feature	0	0	225
Reclassification of warrants to APIC	0	0	2
Supplemental cash flow information	'	'	'
Interest payments	$0	$0	$61

GENERAL

GENERAL	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature Of Operations [Text Block]	'
	1	GENERAL
	Amarantus Bioscience Holdings, Inc. (the “Company”) is a Nevada corporation that was formed to facilitate a merger with Amarantus BioScience, Inc., a Delaware corporation that was incorporated on January 14, 2008. The Company is a development stage biopharmaceutical drug development company dedicated to sourcing high-potential therapeutic platform technologies and aligning their development with complementary clinical-stage compounds to reduce overall enterprise risk. Through March 31, 2014, the Company has been primarily engaged in biotechnology research and development and raising capital to fund its operations.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.
	The unaudited condensed consolidated financial statements (Financial Statements) have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments (consisting of normal recurring adjustments unless otherwise indicated) which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Certain prior year amounts have been reclassified to conform to current year presentation.
	Certain information in footnote disclosures normally included in the financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the SEC rules and regulations for interim reporting. The financial results for the periods presented may not be indicative of the full year’s results. The Company believes the disclosures are adequate to make the information presented not misleading.
	These financial statements should be read in conjunction with the Company’s audited consolidated  financial statements and the notes thereto for the fiscal year ended December 31,, 2013 included in the Company’s Annual Report on Form 10K filed in April 2014.
	Significant Accounting Policies
	There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2013 Annual Report.
	Recently Issued Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the three months ended March 31, 2014, as compared to the recent accounting pronouncements described in the Company’s Form 10-K for the year ended December 31, 2013, that are of significance, or potential significance, to the Company.

LIQUIDITY_AND_GOING_CONCERN

LIQUIDITY AND GOING CONCERN	3 Months Ended
	Mar. 31, 2014
Liquidity And Going Concern [Abstract]	'
Liquidity And Going Concern [Text Block]	'
	2	LIQUIDITY	and Going Concern
	The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. The Company is considered to be in the development stage as of March 31, 2014, as our principal commercial operations have not commenced. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.
	The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP), which contemplate continuation of the Company as a going concern. As of March 31, 2014, the Company had cash and cash equivalents of approximately $3,765. During the three months ended March 31, 2014, the Company incurred a net loss of approximately $5,542 and had negative cash flows from operating activities of approximately $1,259. In addition, the Company had an accumulated deficit of approximately $32,600 at March 31, 2014. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	At March 31, 2014, the Company was in technical default on certain convertible notes with an aggregate principal balance outstanding of approximately $114, which was due prior to March 31, 2014.

RESTATEMENT_OF_PRIOR_QUARTERS

RESTATEMENT OF PRIOR QUARTERS	3 Months Ended
	Mar. 31, 2014
Accounting Changes and Error Corrections [Abstract]	'
Accounting Changes and Error Corrections [Text Block]	'
	3	RESTATEMENT  OF PRIOR QUARTERS
	In the fourth quarter of 2013, we discovered that some of the amounts we had previously reported in prior quarters had not been recorded correctly. The adjustments to correct for accounting differences were made in the fourth quarter of 2013 and are primarily related to our accounting for convertible note obligations.
	The following table sets forth the effects of the restatement on affected items within our previously reported Condensed Consolidated Statement of Operations for the three months ended March 31, 2013.
			Three Months Ended March 31, 2013
			As Reported		As Restated
	Operating loss		$	-1,636	$	-1,885
	Non-operating income (loss)			-3,906		-2,753
	Net loss			-5,542		-4,638
	Net loss per common share, basic and diluted		$	-0.01	$	-0.01

BALANCE_SHEET_DETAILS

BALANCE SHEET DETAILS	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Supplemental Balance Sheet Disclosures [Text Block]	'
	4	BALANCE SHEET DETAILS
	Deferred funding fees:
			Period Ended
			March 31,		December 31,
			2014		2013
	Total deferred funding fees		$	266	$	150
	Amortization			-137		-41
	Net deferred funding fees		$	129	$	109
	The net deferred funding fees consist mainly of approximately $116 relating to the commitment fee paid to Lincoln Park Fund, LLC.
	As of March 31, 2014, amortization expense for the next three years is expected to be as follows:
	2014 (remaining nine months)		$	48
	2015			46
	2016			35
	Total		$	129
	Accrued liabilities:
			Period Ended
			March 31,		December 31,
			2014		2013
	Accrued compensation and related benefits		$	197	$	267
	Series D Convertible Preferred dividend payable			26		26
	Total		$	223	$	293
	Related party liabilities:
			Period Ended
			March 31,		December 31,
			2014		2013
	Promissory note		$	222	$	222
	Accrued interest			27		26
	Total		$	249	$	248
	This promissory note dated March 5, 2008 is due and payable March 5, 2015 and carries an annual interest rate of 2%. At the option of the Company, the This note and the accrued interest owed can be converted to the common stock of the Company based on the closing price on the day of the conversion as quoted on the exchange on which the Company’s common stock is listed. The conversion price as at March 31, 2014 was $0.0775  and would convert to approximately 3,213,000 shares.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	5	Fair Value Measurements
	The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013, by level within the fair value hierarchy, are as follows:
	Fair Value Measurements at March 31, 2014
			Level 1			Level 2			Level 3			Total
	Derivative Liability		$	—		$	—		$	409		$	409
	Fair Value Measurements at December 31, 2013
			Level 1			Level 2			Level 3			Total
	Derivative Liability		$	—		$	—		$	5,859		$	5,859
	For certain convertible note obligations, the Company is required to measure and record a related derivative liability, representing the estimated fair value of any embedded conversion options.  The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities from December 31, 2013 to March 31, 2014:
	Debenture issuance date		October			October			September			October		October			September			October			September		October			October			September			October		October			Total
			2, 2013			2, 2013			6, 2013			2, 2013		2, 2013			6, 2013			2, 2013			6, 2013		2, 2013			2, 2013			6, 2013			2, 2013		2, 2013
	Number of shares issued (000 omitted)			2,778			2,083			16,667			10,083		1,028			7,500			139			6,806		3,750			13,264			3,889			5,208		1,667
	Debenture principal		$	111		$	83		$	667		$	403	$	41		$	300		$	6		$	272	$	150		$	531		$	156		$	208	$	67		$	2,995
	Fair value of debenture at conversion date (1)		$	204		$	115		$	1,333		$	811	$	46		$	498		$	9		$	388	$	171		$	591		$	220		$	301	$	97		$	4,784
	Date of valuation (conversion)		October				February				January			January				March				February			February				March				March			March				February			February			March
			2, 2013				20, 2014				30, 2014			30, 2014				31, 2014				5, 2014			10, 2014				62,014				20, 2014			31, 2014				12, 2014			12, 2014			4, 2014
	Dividend yield (per share)			0	%			0	%			0	%		0	%			0	%			0	%		0	%			0	%			0	%		0	%			0	%		0	%		0	%
	Exercise price		$	0.04			$	0.04			$	0.04		$	0.04			$	0.04			$	0.04		$	0.04			$	0.04			$	0.04		$	0.04			$	0.04		$	0.04		$	0.04
	Volatility (annual)			134	%			136	%			136	%		132	%			133	%			138	%		134	%			134	%			131	%		133	%			134	%		134	%		132	%
	Risk-free rate			0.07	%			0.08	%			0.06	%		0.0006				0.0009				0.0007			0.001				0.0008				0.0009			0.0007				0.0009			0.009			0.0008
	Remaining life (years)			0.66				0.61				0.6			0.67				0.51				0.58			0.64				0.5				0.54			0.51				0.56			0.64			0.58
	The following table are the Level 3 Weighted Average reports associated with the derivative liabilities at March 31, 2014:
	Exercise Price		$	0.04
	Volatility			129	%
	Risk-free Rate			0.07	%
	Contractual Life			0.5
	Dividend Yield			0	%
			Derivative
			Liability
	31-Dec-13		$	5,859
	Conversion of 8% senior convertible debentures to common stock (1)			-4,784
	Change in fair value			-666
	31-Mar-14		$	409
		-1	The $4,784 was included with the debt discount in the statement of equity as result of the conversions of the convertible debt.

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	6	Net loss per share
	The following table sets forth the computation of the basic and diluted net loss per share attributable to Amarantus common stockholders for the periods indicated:
			For the Three Months Ended
			March 31,
			2014			2013 (restated)
	Numerator
	Net loss		$	-5,542		$	-4,638
	Preferred stock dividend			26			—
	Net loss applicable to common stockholders		$	-5,568		$	-4,638
	Denominator
	Weighted average shares outstanding during the period:
			For the Three Months Ended
			March 31,
			2014			2013 (restated)
	Common stock - basic			630,720,618			368,215,835
	Common shares equivalents			—			—
	Common stock - diluted			630,720,618			368,215,835
	Net loss per share		$	-0.01		$	-0.01
	Potentially dilutive securities:
	Outstanding time-based common stock options(1)		14,296,000		-2
	Outstanding performance-based and market-based common stock options(1)		4,000,000		-2
	Outstanding time-based preferred stock options(1)		2,488,000		-2
	Warrants(1)		69,553,000		-2
	Related party liability(1)		3,214,000		-2
	Convertible promissory note(s)(1)		5,655,000		-2
	8% Senior convertible debentures		8,776,000		-2
	Convertible preferred stock(1) (3)		751,000		-2
			-1	The impact of time-based, performance-based and market-based stock options, time-based restricted stock units, warrants, the convertible notes and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.
			-2	Total anti dilutive securities for the 3 months ended March 31,  2013 was approximately 71,000,000.
			-3	Includes convertible preferred Series C and D.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	7	intangible assets
	The following table summarizes our intangible assets:
			Period  Ended
			March 31,		December 31,
			2014		2013
	Intangible assets:
	Licenses		$	1,431	$	681
	Accumulated amortization			-93		-70
	Total intangible assets net		$	1,338	$	611
	These license costs will be amortized over the expected remaining lives of the respective patents. As of March 31, 2014, amortization expense for the next five years is expected to be as follows:
	2014 (remaining nine months)		$	78
	2015			102
	2016			102
	2017			102
	2018			102
	thereafter			852
	Total		$	1,338
	Eltoprazine License
	On January 10, 2014, the Company entered into a license agreement with PGI Drug Discovery, LLC (“PGI”), which granted the Company an exclusive license (with a right to sublicense) to utilize certain licensed compounds and licensed products of PGI, which includes certain intellectual property and know how covering the use of Eltoprazine and certain of its related compounds in all therapeutic indications.
	The Company has agreed to: (i) pay PGI $100 in cash for the License within 20 days of the execution of the License Agreement, (ii) pay a research support payment to PGI as partial reimbursement for costs incurred for earlier research totaling up to $650 to be paid in a mixture of cash and stock, (iii) reimburse PGI for the Eltoprazine clinical trial material up to $500 payable upon the earlier of the initiation of a Phase IIb clinical study or 6 months after the date of the License Agreement, and (iv) pay PGI up to an aggregate of $4,000 in development milestones through NDA submission. As further consideration for the License Agreement, the Company shall pay an 8% royalty to PGI of the annual aggregate net sales by the Company.
	Simultaneous with the execution of the license agreement, the Company and PGI entered into a services agreement pursuant to which PGI will provide certain services to the Company related to PGI’s proprietary analytical systems as will be set forth in certain study plans. The Company agreed to a payment commitment of $450 at a minimum annual rate of $150 for each of three years. The Services Agreement is for a term of the later of 3 years or the completion of any study plan accepted by the parties under the services agreement.
	As of March 31, 2014, as a result of the arrangement described above, the Company recorded the following: (i) $500 in cash payments along with  4,000,000 shares of common stock valued at $250 as an intangible asset, (ii) $500 as an asset related to the transferred clinical trial material, and (iii) liabilities of $500 to be paid to PGI for the clinical trial material and $22 for unissued shares.

8_SENIOR_CONVERTIBLE_DEBENTURE

8% SENIOR CONVERTIBLE DEBENTURES (8% Senior Convertible Debentures [Member])	3 Months Ended
	Mar. 31, 2014
8% Senior Convertible Debentures [Member]	'
Debt Disclosure [Text Block]	'
	8	8% Senior convertible debentures
	The following table summarizes the Company’s outstanding 8% convertible promissory note obligations:
			Maturity	Stated			Principal Balance Outstanding
				Interest
	Issue Date		Date	Rate		Conversion Terms	March 31, 2014		December 31, 2013
	10/2/13		10/2/14	8	%	Variable conversion price currently at $0.04	$	150	$	1,789
	9/6/13		9/6/14	8	%	Variable conversion price, currently at $0.04		189		1,544
			Sub total					339		3,333
			Discount					-161		-2,401
			Current portion of 8% convertible promissory notes, net of debt discount				$	178	$	932
	During the three months ended March 31, 2014 approximately $3,091, consisting of approximately $2,995 of debentures and approximately $96 of accrued interest of the 8% senior convertible debentures, converted to 77,405,866 shares of common stock of the Company. Additionally, $1,740 of the 8% senior convertible debentures related debt discount was reclassified from liability to additional paid in capital.
	The Company entered into a registration rights agreement with the Investors pursuant to which the Company filed a registration statement with the Securities and Exchange Commission. The registration statement went effective February 4, 2014.

CONVERTIBLE_PROMISSORY_NOTES

CONVERTIBLE PROMISSORY NOTES (Convertible Promissory Notes Payable [Member])	3 Months Ended
	Mar. 31, 2014
Convertible Promissory Notes Payable [Member]	'
Debt Disclosure [Text Block]	'
	9	Convertible Promissory Notes
	The following table summarizes the Company’s outstanding convertible promissory note obligations:
				Stated			Principal Balance Outstanding
	Issue Date		Maturity Date	Interest		Conversion Terms	March 31,		December 31,
				Rate			2014		2013
	6/5/13		12/2/13	6	%	Fixed at $0.02		20		20
	11/4/12		5/3/13	6	%	Fixed at $0.01		-		10
	8/23/12		2/19/13	6	%	Fixed at $0.015		50		50
	Nov-12		On Demand	None		Refundable excess payment		1		1
	6/6/11		6/6/13	5	%	Variable at $0.04		10		10
	4/11/11		4/11/13	5	%	Variable at $0.04		25		25
	5/1/11		5/1/13	5	%	Fixed at $0.10		4		4
	4/1/11		4/1/13	5	%	Fixed at $0.10		4		4
			Total convertible promissory notes				$	114	$	124
	Convertible notes converted to common stock
	On February 10, 2014 Robert L. Harris, a member of the Board of Directors, converted his $10 note and $1 accrued interest into 1,095,759 shares of restricted common stock.
	Convertible notes in default
	At March 31, 2014, the Company was in technical default on certain convertible notes with an aggregate principal balance outstanding of approximately $114, which was due prior to March 31, 2014.

DEMAND_PROMISSORY_NOTE

DEMAND PROMISSORY NOTE (Demand Deposits [Member])	3 Months Ended
	Mar. 31, 2014
Demand Deposits [Member]	'
Debt Disclosure [Text Block]	'
	10	DEMAND PROMISSORY NOTE
	On February 14, 2014, the Company executed a Demand Promissory Note payable to Dominion Capital, LLC in the amount of $500 at an annual interest rate of 12% compounded monthly until the note is repaid. On March 12, 2014, , the Company elected to extend the maturity of the Note from March 14, 2014 to August 14, 2014.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	11	commitments and contingencies
	Commitments:
	Lease Arrangements — The Company leases its main office facility and laboratory space in San Francisco, CA under a one-year lease agreement with QB3 Incubator Partners, LP. The lease agreement was entered into in October 2013 and provides for rental payments of approximately $7 per month.
	Rent expense for the three months ended March 31, 2014 and  2013 was approximately $21 and $8, respectively.
	The Company and PGI entered into a services agreement pursuant to which PGI will provide certain services to the Company related to PGI’s proprietary analytical systems (refer to Note INTANGABLE ASSETS). The Company agreed to a payment commitment of $450 at a minimum annual rate of $150, for each of three years. The Services Agreement is for a term of the later of 3 years or the completion of any study plan accepted by the parties under the services agreement.
	Pursuant to the December 12, 2013 license agreement between the Company and the University of Massachusetts, the Company is required to pay an annual license maintenance fee of $15 as long as the agreement remains in effect and the related patents remain valid. The Company is also obligated to reimburse the university for all patent costs incurred that are related to the licensed patents for the duration of the agreement term.
	Contingencies:
	On January 10, 2014, the Company entered into a license agreement (“PGI License Agreement”) with PGI Drug Discovery, LLC (“PGI”). Pursuant to the terms of the agreement, the Company agreed to pay PGI up to an aggregate of $4,000 in development milestones through NDA submission. Milestone based payments payable by the Company under the PGI License Agreement are as follows: (i) $1,000 upon successful completion of the first Phase 2b clinical study, and (ii) $3,000 million upon submission of a New Drug Application with the United States Food and Drug Administration or a comparable submission outside of the United States.
	Pursuant to the LPC Purchase Agreement (refer to Note COMMON STOCK PRIVATE PLACEMENTS), the Company may be required to issue up to 3,500,000 shares of common stock to LPC on a pro rata basis if and when the Company utilizes funding available under the agreement.
	Pursuant to the MDx Purchase Agreement (refer to Note SUBSEQUENT EVENTS) and contingent upon (i) the Company entering into a direct licensing agreement with the University of Leipzig (“Leipzig”) pursuant to which Leipzig would grant the Company a direct license to certain assets now licensed to MDx by Leipzig, and (ii) MDx terminating the license agreement it currently holds with Leipzig with the Company’s prior written consent, the Company has agreed to issue to MDx 6,500,000 shares of the Company’s common stock and will provide MDx with piggy-back registration rights as it relates to such shares.
	Pursuant to the December 12, 2013 license agreement between the Company and the University of Massachusetts, the Company is obligated to pay the university certain amounts in the event certain events occur or milestones are achieved. Milestones to be paid under the agreement are as follows: (i) $50 upon first human dosing, (ii) $75 upon initiation of first Phase 2 clinical trial, (iii) $100 upon initiation of first Phase 3 clinical trial, and (iv) $500 upon first product approval in the United States. Following commercial launch, the Company is required to pay a royalty to the university equal to 2% of net sales, as defined under the agreement, subject to certain royalty minimums ranging from $125 to $500 per year. The Company is also obligated to pay to the university 10% of any sub-license income generated under the agreement.
	The Company is in technical default  of certain convertible notes that were due prior to March 31, 2014, and is also late with regard to making payments to various trade account vendors for goods and services received. Presently the Company is not aware of any accounts that have been turned over to collection agencies or that might result in a lawsuit with the Company.

COMMON_STOCK_WARRANTS

COMMON STOCK WARRANTS	3 Months Ended
	Mar. 31, 2014
Common Stock Warrants Abstract [Abstract]	'
Common Stock Warrants Disclosure [Text Block]	'
	12	COMMON STOCK WARRANTS
	Stock Warrants
	The Company issued 83,333,251 Warrants in 2013 in connection with the Debenture and Warrant transaction. The Warrants are exercisable for a term of three years from the date of issuance at an exercise price of $0.06 per share. The Warrants are exercisable on a cashless basis if at any time after the six months anniversary there is no effective registration statement or current prospectus available for the resale of the shares underlying the Warrants. The Company may call the warrants at an exercise price of $.001 per share if certain conditions as described in the Warrant are met. On February 4, 2014, the Company registered these warrants with the SEC.
	On March 7, 2014, the Company accepted elections by warrant holders to exercise certain warrants in the aggregate amount of 60,000,000 shares of common stock for gross proceeds of $3,600.  Pursuant to the offer to exercise dated February 13, 2014 as supplemented on March 6, 2014, the holders of outstanding warrants to purchase shares of common stock of the Company at a price of $0.06 (the “Original Warrants”) were offered the opportunity to exercise their Original Warrants and receive warrants (the “New Warrants”) to purchase three (3) shares of common stock of the Company for every four (4) Original Warrants exercised. The New Warrants are exercisable at any time at a price of $0.12 for a term of five (5) years. The New Warrants are callable by the Company if the Volume Weighted Average Price (VWAP) of the Company’s common stock for each of 20 consecutive trading days exceeds $0.18 and certain equity conditions are met. The Company may also call the New Warrants if the closing price of the Company’s common stock exceeds $0.18 on the date that is the earlier of the receipt by the Company of an approval letter for listing of the Company’s common stock on an exchange or actual listing of the common stock on an exchange. The holders of the New Warrants have piggy back – registration rights. Upon the closing of the offer to exercise the Company issued New Warrants to purchase 45,000,000 shares of common stock of the Company.
	In accordance with ASC 815-40-25-10 the Company determined that the appropriate accounting treatment of the New Warrants is to determine the Black-Scholes value of the warrant and to record the fair value of the warrant as a loss upon Issuance of Warrants in the Other income (expense) section of the statement of operations along with a credit to Additional paid-In capital. The fair value was determined to be approximately $3,867, using the Black-Scholes model with the following weighted average assumptions at issuance:
	Annualized volatility(1)		305	%
	Contractual term		5
	Risk-free investment rate		1.65	%
	Dividend yield		0	%
	(1) - The Company has three years of trading history that was utilized in computing the annualized volatility as of the date of issuance.
	The following table summarizes the Company’s warrant activity for the three months ended March 31, 2014.
			Number of		Weighted Average	Weighted Average
			Warrants		Exercise Price	Remaining Contractual
						Term
	Outstanding warrants as of December 31, 2013		84,553,306		0.06	2.7
	Exercised		-60,000,000		0.06	2.7
	Issued as a result of the above exercise		45,000,000		0.12	4.9
	Outstanding warrants as of March 31, 2014		69,553,306		0.1	4

COMMON_STOCK_PRIVATE_PLACEMENT

COMMON STOCK PRIVATE PLACEMENTS	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Common Stock Note Disclosure [Text Block]	'
	13	COMMON STOCK Private placements
	On March 7, 2014, the Company entered into an equity financing agreement (“LPC Purchase Agreement”) with Lincoln Park Capital Fund LLC (“LPC”) whereby LPC is obligated to purchase up to $20,000 of the Company’s common stock from time to time over a 30 month period, as directed by the Company and subject to certain requirements, restrictions and limitations. Under the agreement, the per share purchase price will be the lesser of (1) the lowest sale price of common stock on the purchase date and (2) the average of the three lowest closing purchase prices during the 10 consecutive business days prior to the purchase date. However, LPC is not obligated to purchase shares from the Company on any date that the closing price of the common stock is below $0.04, subject to adjustment upon the occurrence of certain stock related events. The Company may also request that LPC purchase shares under an accelerated purchase notice whereby the per share purchase price will be the lower of (i) 94% of a volume weighted average price calculation as determined under the agreement or (ii) the closing price of the common stock on the accelerated purchase date.
	In consideration for entering into the agreement, the Company agreed to issue 9,500,000 shares of common stock to LPC, 6,000,000 of which were issued upon entering into the agreement and 3,500,000 of which are contingently issuable on a pro rata basis as the Company utilizes the financing arrangement. The agreement will automatically terminate upon the earliest of 30 months or upon full utilization of the purchase commitment.
	Pursuant to the agreement, the Company sold an initial 4,000,000 shares to LPC for an aggregate gross purchase price of $400. The fair value of the 6,000,000 shares provided to LPC was approximately $516 and was treated as a deferred funding fee. $400 was considered a placement fee against the $400 raised pursuant to execution of the LPC Purchase Agreement. The remaining $116 of deferred funding fees will be offset against future capital raises.

STOCK_OPTION_PLANS

STOCK OPTION PLANS	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	14	STOCK OPTION PLANS
	2008 Stock Plan
	The Company’s Board of Directors approved the 2008 Stock Plan (the “Plan”). Under the Plan, the Company may grant up to 38,242,127 options, including 10,000,000 the Board added to the plan in January, of incentive stock options, nonqualified stock options, or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years.
	The following table is a summary of activity under the Plan:
							Outstanding
							Options
							Common
		Common Stock			Weighted Average		Weighted
		options			Exercise Price		Average
		outstanding					Remaining
							Contractual
							Term
	Balance – December 31, 2013		6,941,288			0.05		9
	Options granted (weighted-average fair value of $0.057)
	Employee		8,200,000			0.08		10
	Non-Employee		3,154,839			0.08		10
	Options cancelled		—			—		—
	Options Exercised		—			—		—
	Balance –March 31, 2014		18,296,127			0.07		9.5
	Options vested as of March31, 2014		8,774,622
	The 8,200,000 shares granted to Employees include 8,000,000 shares granted to the Company’s new Chief Financial Officer (See Note, Subsequent Events), 4,000,000 of which are time-based and vest 25 percent upon grant and 1/36 per month thereafter during continued service; 2,000,000 of which are performance-based and vest upon continued service and achievement of a specific goal; and 2,000,000 of which are market-based and vest upon continued service and the Company’s achievement of certain stock price targets. All of the 8,000,000 shares are at an exercise price of $0.0775 and were granted on March 31, 2014.
	During the three months ended March 31, 2014, the Company granted stock options and awards that were greater than the shares authorized, resulting in a deficit of shares available in the Plan of 3,231,221 as of March 31, 2014. The Company expects the Board of Directors will authorize additional shares for the Plan by June 2014 to offset the deficit.
	2012 Preferred Stock Plan
	In July 2012, our Board of Directors adopted a new stock plan, the Management, Employee, Advisor and Director Preferred Stock Option Plan – 2012 Series B Convertible Preferred Stock Plan (“Preferred Stock Plan”). The purposes of the Preferred Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Management, Employees, Advisors and Directors and to promote the success of our business.  These options currently vest over two or three years and cannot be converted into common shares or sold for two years from the date of the Designation of the Series B Preferred shares. Each share of Series B Preferred stock converts into fifty shares of common stock. The following table is a summary of activity under the Preferred Stock Plan:
							Outstanding
							Preferred
							Options
		Preferred Stock			Weighted Average		Weighted
		Options			Exercise Price		Average
		Outstanding					Remaining
							Contractual
							Term
	Balance – December 31, 2013		2,287,500			0.47		8.5
	Preferred options cancelled		—			—		—
	Preferred options granted (weighted-average fair value of $1.61)
	Employee		200,000			2.21		9.8
	Non-Employee		—			—		—
	Balance – March 31, 2014		2,487,500			0.61		8.6
	Preferred options vested as of March 31, 2014		1,482,161
	Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized, Series B, $0.001 par value:
	As of March 31, 2014, Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized, Series B, $0.001 par value, indicates 3,000,000 shares designated, but the Company’s Form 10-K for the year ended December 31, 2013 indicates 2,500,000 shares designated. The Company’s Form 10-K for the year ended December 31, 2013, did not include the increase of 500,000 designated shares approved by the Board of Directors on November 20, 2013. This oversight has no effect on any of the financial information presented in the Company’s Form 10-K for the year ended December 31, 2013.
	Stock-based compensation expense for all plans is classified in the statements of operations as follows:
		Three Months Ended March 31,
		2014			2013
	Research and development	$	78		$	282
	General and administrative		124			226
	Total	$	202		$	508
	At March 31, 2014, there was a total of approximately $1,043 of unrecognized compensation cost, net of estimated forfeitures of zero,  as the Company has not experienced any forfeitures to date, related to non-vested stock option awards, which is expected to be recognized over a weighted-average period of approximately 2.5 years.
	The fair value of the Company’s stock-based awards during the three months ended March 31, 2014 and 2013 were estimated using the Black-Scholes option-pricing model with the following assumptions:
		Three Months Ended March 31,
		2014		2013
	Weighted-average volatility	89.2	%	108	%
	Weighted-average expected term	5		5
	Expected dividends	0	%	0	%
	Risk-free investment rate	1.65	%	0.5	%

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	15	RElated-Party Transactions
	On February 10, 2014 Robert L. Harris, a member of the Board of Directors, converted his $10 note and $1 accrued interest into 1,095,759 shares of restricted common stock.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	16	SUBSEQUENT EVENTS
	Appointment of the Company’s New Chief Financial Officer
	On April 1, 2014, Robert Farrell, J.D. was appointed to serve as the Company’s Chief Financial Officer. Mr. Marc Faerber, the former CFO, will now serve as the Company’s Corporate Controller and Vice President of Financial Operations.
	Mr. Farrell served as Chief Financial Officer of Titan Pharmaceuticals from 1996 to 2008, and as President and CEO from 2008 to 2010. During his tenure at Titan Mr. Farrell was responsible for all SEC filings, fund raising, financial and tax planning strategies, mergers  and acquisitions, corporate partnerships, licensing transactions and financial operations. Mr. Farrell most recently served as CFO at Sanovas, Inc. Mr. Farrell previously served as CFO, Corporate Group Vice President and General Counsel at Fresenius USA and Fresenius Medical Care. Mr. Farrell also previously served as the CFO for the Institute for One World Health in San Francisco and currently serves on the Board of Directors of Prime Genomics, Inc. Mr. Farrell holds a J.D. from the University of California's Hastings School of Law.
	Mr. Farrell will initially be engaged as a contract consultant but is expected to be a full-time employee by the end of June 2014 upon execution of an employment agreement.
	Asset purchase agreement with Memory Dx, LLC
	On April 29, 2014, the Company entered into an asset purchase agreement (“MDx Purchase Agreement”) with Memory Dx, LLC (“MDx”), pursuant to which the Company purchased all of the assets of MDx, including all right, title and interest in the LymPro Technology, (as defined in the MDx Purchase Agreement). Such assets include all intellectual property, goodwill, patents and all copyrights owned by MDx, subject to certain exclusions as further described in the MDx Purchase Agreement.
	As consideration for transfer of the assets, the Company agreed to pay to MDx (i) $50 upon execution of the MDx Purchase Agreement, (ii) $50 upon the date 60 days after execution of the MDx Purchase Agreement, and (iii) $50 on the date 120 days after execution of the MDx Purchase Agreement. Additionally, the Company agreed to issue to MDx upon delivery of the assets, 1,500,000 shares of the Company’s common stock and provide MDx with piggy-back registration rights as it relates to such shares.
	Contingent upon (i) the Company entering into a direct licensing agreement with the University of Leipzig (“Leipzig”) pursuant to which Leipzig would grant the Company a direct license to certain assets now licensed to MDx by Leipzig, and (ii) MDx terminating the license agreement it currently holds with Leipzig as it relates to such licensed assets with the Company’s prior written consent, the Company has agreed to issue to MDx 6,500,000 shares of the Company’s common stock and will provide MDx with piggy-back registration rights as it relates to such shares. The previous laboratory services agreement entered into between Amarantus and MDx on April 2, 2013 was terminated following execution of the MDx Purchase Agreement.
	Asset purchase agreement with Provista Diagnostics, Inc.
	On May 1, 2014, the Company entered into an asset purchase agreement with Provista Diagnostics, Inc. (“PDI”) to acquire certain assets related to fluorescently activated cell sorter (FACS) related equipment, software and data. In exchange for these assets, the Company agreed to pay to PDI a one-time payment of $20.

GENERAL_Policies

GENERAL (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the three months ended March 31, 2014, as compared to the recent accounting pronouncements described in the Company’s Form 10-K for the year ended December 31, 2013, that are of significance, or potential significance, to the Company.

RESTATEMENT_OF_PRIOR_QUARTERS_

RESTATEMENT OF PRIOR QUARTERS (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Changes and Error Corrections [Abstract]	'
Restatement to Prior Year Income [Table Text Block]	'
	The following table sets forth the effects of the restatement on affected items within our previously reported Condensed Consolidated Statement of Operations for the three months ended March 31, 2013.
		Three Months Ended March 31, 2013
		As Reported		As Restated
	Operating loss	$	-1,636	$	-1,885
	Non-operating income (loss)		-3,906		-2,753
	Net loss		-5,542		-4,638
	Net loss per common share, basic and diluted	$	-0.01	$	-0.01

BALANCE_SHEET_DETAILS_Tables

BALANCE SHEET DETAILS (Tables)	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule Of Deferred Costs [Table Text Block]	'
	Deferred funding fees:
		Period Ended
		March 31,		December 31,
		2014		2013
	Total deferred funding fees	$	266	$	150
	Amortization		-137		-41
	Net deferred funding fees	$	129	$	109
Schedule of Amortization Expense Of Deferred Costs [Table Text Block]	'
	As of March 31, 2014, amortization expense for the next three years is expected to be as follows:
	2014 (remaining nine months)	$	48
	2015		46
	2016		35
	Total	$	129
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities:
		Period Ended
		March 31,		December 31,
		2014		2013
	Accrued compensation and related benefits	$	197	$	267
	Series D Convertible Preferred dividend payable		26		26
	Total	$	223	$	293
Schedule of Related Party Transactions [Table Text Block]	'
	Related party liabilities:
		Period Ended
		March 31,		December 31,
		2014		2013
	Promissory note	$	222	$	222
	Accrued interest		27		26
	Total	$	249	$	248

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013, by level within the fair value hierarchy, are as follows:
	Fair Value Measurements at March 31, 2014
			Level 1			Level 2			Level 3			Total
	Derivative Liability		$	—		$	—		$	409		$	409
	Fair Value Measurements at December 31, 2013
			Level 1			Level 2			Level 3			Total
	Derivative Liability		$	—		$	—		$	5,859		$	5,859
Schedule Of Changes In Fair Value Of Level 3 Financial Liabilities [Table Text Block]	'
	The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities from December 31, 2013 to March 31, 2014:
	Debenture issuance date		October			October			September			October		October			September			October			September		October			October			September			October		October			Total
			2, 2013			2, 2013			6, 2013			2, 2013		2, 2013			6, 2013			2, 2013			6, 2013		2, 2013			2, 2013			6, 2013			2, 2013		2, 2013
	Number of shares issued (000 omitted)			2,778			2,083			16,667			10,083		1,028			7,500			139			6,806		3,750			13,264			3,889			5,208		1,667
	Debenture principal		$	111		$	83		$	667		$	403	$	41		$	300		$	6		$	272	$	150		$	531		$	156		$	208	$	67		$	2,995
	Fair value of debenture at conversion date (1)		$	204		$	115		$	1,333		$	811	$	46		$	498		$	9		$	388	$	171		$	591		$	220		$	301	$	97		$	4,784
	Date of valuation (conversion)		October				February				January			January				March				February			February				March				March			March				February			February			March
			2, 2013				20, 2014				30, 2014			30, 2014				31, 2014				5, 2014			10, 2014				62,014				20, 2014			31, 2014				12, 2014			12, 2014			4, 2014
	Dividend yield (per share)			0	%			0	%			0	%		0	%			0	%			0	%		0	%			0	%			0	%		0	%			0	%		0	%		0	%
	Exercise price		$	0.04			$	0.04			$	0.04		$	0.04			$	0.04			$	0.04		$	0.04			$	0.04			$	0.04		$	0.04			$	0.04		$	0.04		$	0.04
	Volatility (annual)			134	%			136	%			136	%		132	%			133	%			138	%		134	%			134	%			131	%		133	%			134	%		134	%		132	%
	Risk-free rate			0.07	%			0.08	%			0.06	%		0.0006				0.0009				0.0007			0.001				0.0008				0.0009			0.0007				0.0009			0.009			0.0008
	Remaining life (years)			0.66				0.61				0.6			0.67				0.51				0.58			0.64				0.5				0.54			0.51				0.56			0.64			0.58
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	'
	The following table are the Level 3 Weighted Average reports associated with the derivative liabilities at March 31, 2014:
	Exercise Price		$	0.04
	Volatility			129	%
	Risk-free Rate			0.07	%
	Contractual Life			0.5
	Dividend Yield			0	%
Summary of Changes in the Fair value of the Companys Level 3 Financial Liability [Table Text Block]	'
			Derivative
			Liability
	31-Dec-13		$	5,859
	Conversion of 8% senior convertible debentures to common stock (1)			-4,784
	Change in fair value			-666
	31-Mar-14		$	409
		-1	The $4,784 was included with the debt discount in the statement of equity as result of the conversions of the convertible debt.

NET_LOSS_PER_SHARE_Tables

NET LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule Of Net Income Loss Per Share [Table Text Block]	'
	The following table sets forth the computation of the basic and diluted net loss per share attributable to Amarantus common stockholders for the periods indicated:
		For the Three Months Ended
		March 31,
		2014			2013 (restated)
	Numerator
	Net loss	$	-5,542		$	-4,638
	Preferred stock dividend		26			—
	Net loss applicable to common stockholders	$	-5,568		$	-4,638
	Denominator
	Weighted average shares outstanding during the period:
		For the Three Months Ended
		March 31,
		2014			2013 (restated)
	Common stock - basic		630,720,618			368,215,835
	Common shares equivalents		—			—
	Common stock - diluted		630,720,618			368,215,835
	Net loss per share	$	-0.01		$	-0.01
	Potentially dilutive securities:
	Outstanding time-based common stock options(1)	14,296,000		-2
	Outstanding performance-based and market-based common stock options(1)	4,000,000		-2
	Outstanding time-based preferred stock options(1)	2,488,000		-2
	Warrants(1)	69,553,000		-2
	Related party liability(1)	3,214,000		-2
	Convertible promissory note(s)(1)	5,655,000		-2
	8% Senior convertible debentures	8,776,000		-2
	Convertible preferred stock(1) (3)	751,000		-2
		-1	The impact of time-based, performance-based and market-based stock options, time-based restricted stock units, warrants, the convertible notes and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.
		-2	Total anti dilutive securities for the 3 months ended March 31,  2013 was approximately 71,000,000.
		-3	Includes convertible preferred Series C and D.

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	'
	The following table summarizes our intangible assets:
		Period  Ended
		March 31,		December 31,
		2014		2013
	Intangible assets:
	Licenses	$	1,431	$	681
	Accumulated amortization		-93		-70
	Total intangible assets net	$	1,338	$	611
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	These license costs will be amortized over the expected remaining lives of the respective patents. As of March 31, 2014, amortization expense for the next five years is expected to be as follows:
	2014 (remaining nine months)	$	78
	2015		102
	2016		102
	2017		102
	2018		102
	thereafter		852
	Total	$	1,338

8_SENIOR_CONVERTIBLE_DEBENTURE1

8% SENIOR CONVERTIBLE DEBENTURES (Tables) (8% Senior Convertible Debentures [Member])	3 Months Ended
	Mar. 31, 2014
8% Senior Convertible Debentures [Member]	'
Schedule of Debt [Table Text Block]	'
	The following table summarizes the Company’s outstanding 8% convertible promissory note obligations:
		Maturity	Stated			Principal Balance Outstanding
			Interest
	Issue Date	Date	Rate		Conversion Terms	March 31, 2014		December 31, 2013
	10/2/13	10/2/14	8	%	Variable conversion price currently at $0.04	$	150	$	1,789
	9/6/13	9/6/14	8	%	Variable conversion price, currently at $0.04		189		1,544
		Sub total					339		3,333
		Discount					-161		-2,401
		Current portion of 8% convertible promissory notes, net of debt discount				$	178	$	932

CONVERTIBLE_PROMISSORY_NOTES_T

CONVERTIBLE PROMISSORY NOTES (Tables) (Convertible Promissory Notes Payable [Member])	3 Months Ended
	Mar. 31, 2014
Convertible Promissory Notes Payable [Member]	'
Schedule of Debt [Table Text Block]	'
	The following table summarizes the Company’s outstanding convertible promissory note obligations:
			Stated			Principal Balance Outstanding
	Issue Date	Maturity Date	Interest		Conversion Terms	March 31,		December 31,
			Rate			2014		2013
	6/5/13	12/2/13	6	%	Fixed at $0.02		20		20
	11/4/12	5/3/13	6	%	Fixed at $0.01		-		10
	8/23/12	2/19/13	6	%	Fixed at $0.015		50		50
	Nov-12	On Demand	None		Refundable excess payment		1		1
	6/6/11	6/6/13	5	%	Variable at $0.04		10		10
	4/11/11	4/11/13	5	%	Variable at $0.04		25		25
	5/1/11	5/1/13	5	%	Fixed at $0.10		4		4
	4/1/11	4/1/13	5	%	Fixed at $0.10		4		4
		Total convertible promissory notes				$	114	$	124

COMMON_STOCK_WARRANTS_Tables

COMMON STOCK WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2014
Common Stock Warrants Abstract [Abstract]	'
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	'
	The fair value was determined to be approximately $3,867, using the Black-Scholes model with the following weighted average assumptions at issuance:
	Annualized volatility(1)	305	%
	Contractual term	5
	Risk-free investment rate	1.65	%
	Dividend yield	0	%
	(1) - The Company has three years of trading history that was utilized in computing the annualized volatility as of the date of issuance.
Fair Value Warrants Valuation Techniques [Table Text Block]	'
	The following table summarizes the Company’s warrant activity for the three months ended March 31, 2014.
		Number of		Weighted Average	Weighted Average
		Warrants		Exercise Price	Remaining Contractual
					Term
	Outstanding warrants as of December 31, 2013	84,553,306		0.06	2.7
	Exercised	-60,000,000		0.06	2.7
	Issued as a result of the above exercise	45,000,000		0.12	4.9
	Outstanding warrants as of March 31, 2014	69,553,306		0.1	4

STOCK_OPTION_PLANS_Tables

STOCK OPTION PLANS (Tables)	3 Months Ended
	Mar. 31, 2014
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	Stock-based compensation expense for all plans is classified in the statements of operations as follows:
		Three Months Ended March 31,
		2014			2013
	Research and development	$	78		$	282
	General and administrative		124			226
	Total	$	202		$	508
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The fair value of the Company’s stock-based awards during the three months ended March 31, 2014 and 2013 were estimated using the Black-Scholes option-pricing model with the following assumptions:
		Three Months Ended March 31,
		2014		2013
	Weighted-average volatility	89.2	%	108	%
	Weighted-average expected term	5		5
	Expected dividends	0	%	0	%
	Risk-free investment rate	1.65	%	0.5	%
Stock Plan 2008 [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table is a summary of activity under the Plan:
						Outstanding Options
						Common
		Common Stock Options Outstanding		Weighted Average		Weighted Average Remaining Contractual
				Exercise Price		Term
	Balance – December 31, 2013	6,941,288		0.05		9
	Options granted (weighted-average fair value of $0.057)
	Employee	8,200,000		0.08		10
	Non-Employee	3,154,839		0.08		10
	Options cancelled	—		—		—
	Options Exercised	—		—		—
	Balance –March 31, 2014	18,296,127		0.07		9.5
	Options vested as of March 31, 2014	8,774,622
Preferred Stock Plan 2012 [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table is a summary of activity under the Preferred Stock Plan:
							Outstanding
							Preferred
							Options
		Preferred Stock			Weighted Average		Weighted
		Options			Exercise Price		Average
		Outstanding					Remaining
							Contractual
							Term
	Balance – December 31, 2013		2,287,500			0.47		8.5
	Preferred options cancelled		—			—		—
	Preferred options granted (weighted-average fair value of $1.61)
	Employee		200,000			2.21		9.8
	Non-Employee		—			—		—
	Balance – March 31, 2014		2,487,500			0.61		8.6
	Preferred options vested as of March 31, 2014		1,482,161

LIQUIDITY_AND_GOING_CONCERN_De

LIQUIDITY AND GOING CONCERN (Details Textual) (USD $)	3 Months Ended		75 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 13, 2008
Development Stage Enterprises [Line Items]	'	'	'	'	'	'
Cash and cash equivalents	$3,765	$240	$3,765	$1,033	$157	$0
Net loss	-5,542	-4,638	-32,169	'	'	'
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	-1,259	-940	-9,465	'	'	'
Accumulated deficit	-32,600	'	-32,600	-27,032	'	'
Debt Instrument, Debt Default, Amount	$114	'	$114	'	'	'

RESTATEMENT_OF_PRIOR_QUARTERS_1

RESTATEMENT OF PRIOR QUARTERS (Details) (USD $)	3 Months Ended		75 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Restatement Of Prior Year Income [Line Items]	'	'	'
Operating loss	($1,636)	($1,885)	($17,072)
Non-operating income (loss)	-3,906	-2,753	-15,097
Net loss	-5,542	-4,638	-32,169
Net loss per common share, basic and diluted (in dollar per share)	($0.01)	($0.01)	'
Scenario, Previously Reported [Member]	'	'	'
Restatement Of Prior Year Income [Line Items]	'	'	'
Operating loss	'	-1,636	'
Non-operating income (loss)	'	-3,906	'
Net loss	'	($5,542)	'
Net loss per common share, basic and diluted (in dollar per share)	'	($0.01)	'

BALANCE_SHEET_DETAILS_Details

BALANCE SHEET DETAILS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Details [Line Items]	'	'
Total deferred funding fees	$266	$150
Amortization	-137	-41
Net deferred funding fees	$129	$109

BALANCE_SHEET_DETAILS_Details_

BALANCE SHEET DETAILS (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Details [Line Items]	'	'
2014 (remaining nine months)	$48	'
2015	46	'
2016	35	'
Net deferred funding fees	$129	$109

BALANCE_SHEET_DETAILS_Details_1

BALANCE SHEET DETAILS (Details 2) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Details [Line Items]	'	'
Total	$223	$292
Accrued Compensation And Related Benefits [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Total	197	267
Series D Convertible Preferred dividend payable [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Total	$26	$26

BALANCE_SHEET_DETAILS_Details_2

BALANCE SHEET DETAILS (Details 3) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Details [Line Items]	'	'
Total	$249	$248
Promissory Notes Payable [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Total	222	222
Accrued Interest [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Total	$27	$26

BALANCE_SHEET_DETAILS_Details_3

BALANCE SHEET DETAILS (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
			Promissory Notes Payable [Member]
Balance Sheet Details [Line Items]	'	'	'
Debt Instrument, Issuance Date	'	'	5-Mar-08
Debt Instrument, Maturity Date	'	'	5-Mar-15
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%	2.00%
Debt Instrument, Convertible, Conversion Price	'	'	$0.08
Debt Conversion, Converted Instrument, Shares Issued	'	'	3,213,000

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative Liability	$409	$5,859
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative Liability	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative Liability	$409	$5,859

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Debenture principal	$2,995
Fair value of debenture at conversion date	4,784	[1]
Debenture Issuance Date October 2, 2013 [Member]	'
Number of shares issued (000 omitted)	2,778
Debenture principal	111
Fair value of debenture at conversion date	204	[1]
Debenture Issuance Date October 2, 2013 One [Member]	'
Number of shares issued (000 omitted)	2,083
Debenture principal	83
Fair value of debenture at conversion date	115	[1]
Debenture Issuance Date September 6, 2013 [Member]	'
Number of shares issued (000 omitted)	16,667
Debenture principal	667
Fair value of debenture at conversion date	1,333	[1]
Debenture Issuance Date October 2, 2013 Two [Member]	'
Number of shares issued (000 omitted)	10,083
Debenture principal	403
Fair value of debenture at conversion date	811	[1]
Debenture Issuance Date October 2, 2013 Three [Member]	'
Number of shares issued (000 omitted)	1,028
Debenture principal	41
Fair value of debenture at conversion date	46	[1]
Debenture Issuance Date September 6, 2013 One [Member]	'
Number of shares issued (000 omitted)	7,500
Debenture principal	300
Fair value of debenture at conversion date	498	[1]
Debenture Issuance Date October 2, 2013 Four [Member]	'
Number of shares issued (000 omitted)	139
Debenture principal	6
Fair value of debenture at conversion date	9	[1]
Debenture Issuance Date September 6, 2013 Two [Member]	'
Number of shares issued (000 omitted)	6,806
Debenture principal	272
Fair value of debenture at conversion date	388	[1]
Debenture Issuance Date October 2, 2013 Five [Member]	'
Number of shares issued (000 omitted)	3,750
Debenture principal	150
Fair value of debenture at conversion date	171	[1]
Debenture Issuance Date October 2, 2013 Six [Member]	'
Number of shares issued (000 omitted)	13,264
Debenture principal	531
Fair value of debenture at conversion date	591	[1]
Debenture Issuance Date September 6, 2013 Three [Member]	'
Number of shares issued (000 omitted)	3,889
Debenture principal	156
Fair value of debenture at conversion date	220	[1]
Debenture Issuance Date October 2, 2013 Seven [Member]	'
Number of shares issued (000 omitted)	5,208
Debenture principal	208
Fair value of debenture at conversion date	301	[1]
Debenture Issuance Date October 2, 2013 Eight [Member]	'
Number of shares issued (000 omitted)	1,667
Debenture principal	67
Fair value of debenture at conversion date	$97	[1]
Date Of Valuation October 2, 2013 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	134.00%
Risk-free rate	0.07%
Remaining life (years)	'7 months 28 days
Date Of Valuation February 20, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	136.00%
Risk-free rate	0.08%
Remaining life (years)	'7 months 10 days
Date Of Valuation January 30, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	136.00%
Risk-free rate	0.06%
Remaining life (years)	'7 months 6 days
Date Of Valuation January 30, 2014 One [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	132.00%
Risk-free rate	0.00%
Remaining life (years)	'8 months 1 day
Date Of Valuation March 31, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	133.00%
Risk-free rate	0.00%
Remaining life (years)	'6 months 4 days
Date Of Valuation February 5, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	138.00%
Risk-free rate	0.00%
Remaining life (years)	'6 months 29 days
Date Of Valuation February 10, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	134.00%
Risk-free rate	0.00%
Remaining life (years)	'7 months 20 days
Date Of Valuation March 6, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	134.00%
Risk-free rate	0.00%
Remaining life (years)	'6 months
Date Of Valuation March 20, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	131.00%
Risk-free rate	0.00%
Remaining life (years)	'6 months 14 days
Date Of Valuation March 31, 2014 One [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	133.00%
Risk-free rate	0.00%
Remaining life (years)	'6 months 4 days
Date Of Valuation February 12, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	134.00%
Risk-free rate	0.00%
Remaining life (years)	'6 months 22 days
Date Of Valuation February 12, 2014 One [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	134.00%
Risk-free rate	0.01%
Remaining life (years)	'7 months 20 days
Date Of Valuation March 4, 2014 [Member]	'
Dividend yield (per share)	0.00%
Exercise price	$0.04
Volatility (annual)	132.00%
Risk-free rate	0.00%
Remaining life (years)	'6 months 29 days
[1]	The $4,784 was included with the debt discount in the statement of equity as result of the conversions of the convertible debt.

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details 2) (Derivative Liabilities [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Derivative Liabilities [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Exercise Price	$0.04
Volatility	129.00%
Risk-free Rate	0.07%
Contractual Life	'6 months
Dividend Yield	0.00%

FAIR_VALUE_MEASUREMENTS_Detail3

FAIR VALUE MEASUREMENTS (Details 3) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
In Thousands, unless otherwise specified			Derivative Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Balance	$409	$5,859	$5,859
Conversion of 8% senior convertible debentures to common stock	'	'	-4,784	[1]
Change in fair value	'	'	-666
Balance	$409	$5,859	$409
[1]	The $4,784 was included with the debt discount in the statement of equity as result of the conversions of the convertible debt.

FAIR_VALUE_MEASUREMENTS_Detail4

FAIR VALUE MEASUREMENTS (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Debt Conversion Converted Instrument Amount Included In Debt Discount	$4,784

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details) (USD $)	3 Months Ended				75 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013		Mar. 31, 2014
Numerator	'		'		'
Net Loss	($5,542)		($4,638)		($32,169)
Preferred stock dividend	26		0		64
Net loss applicable to common stockholders	($5,568)		($4,638)		($32,233)
Denominator	'		'		'
Common stock - basic (in shares)	630,720,618		368,215,835		'
Common shares equivalents (in shares)	0		0		'
Common stock - diluted (in shares)	630,720,618		368,215,835		'
Net loss per share (in dollars per share)	($0.01)		($0.01)		'
Potentially dilutive securities:	'		'		'
Outstanding time-based common stock options	14,296,000	[1]	0	[1],[2]	'
Outstanding performance-based and market-based common stock options	4,000,000	[1]	0	[1],[2]	'
Outstanding time-based preferred stock options	2,488,000	[1]	0	[1],[2]	'
Warrants	69,553,000	[1]	0	[1],[2]	'
Relating party liabilities	3,214,000	[1]	0	[1],[2]	'
Convertible securities	5,655,000	[1]	0	[1],[2]	'
Convertible preferred stock	751,000	[1],[3]	0	[1],[2],[3]	'
8% Senior Convertible Debentures [Member]	'		'		'
Potentially dilutive securities:	'		'		'
Convertible securities	8,776,000		0	[2]	'
[1]	The impact of time-based, performance-based and market-based stock options, time-based restricted stock units, warrants, the convertible notes and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.
[2]	Total anti dilutive securities for the 3 months ended March 31, 2013 was approximately 71,000,000.
[3]	Includes convertible preferred Series C and D.

NET_LOSS_PER_SHARE_Details_Tex

NET LOSS PER SHARE (Details Textual)	3 Months Ended
	Mar. 31, 2013
Net Income Loss [Line Items]	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	71,000,000

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Accumulated amortization	($93)	($70)
Total intangible assets net	1,338	611
License [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total intangible assets net	$1,431	$681

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
2014 (remaining nine months)	$78	'
2015	102	'
2016	102	'
2017	102	'
2018	102	'
thereafter	852	'
Total	$1,338	$611

INTANGIBLE_ASSETS_Details_Text

INTANGIBLE ASSETS (Details Textual) (USD $)	0 Months Ended			3 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 10, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Jan. 10, 2014
				Eltoprazine In-License Agreement [Member]	Eltoprazine In-License Agreement [Member]
				PGI Services Agreement [Member]	PGI Drug Discovery, LLC [Member]
Indefinite-lived Intangible Assets [Line Items]	'	'	'	'	'
Royalty Percentage	'	'	'	'	8.00%
License Agreement Date Of Agreement	'	'	'	'	10-Jan-14
Payment Of License Agreement Milestone Development Cost	$4,000	'	'	'	$4,000
Payment For Clinical Trials	'	'	'	'	650
Payment Of License Agreement Inventory Cost	'	'	'	'	500
Payment Of License Agreement Cost	'	'	'	500	100
Operating Leases, Future Minimum Payments Due, Total	'	'	'	450	'
Operating Leases, Future Minimum Payments Due, Next Twelve Months	'	'	'	150	'
Operating Leases, Future Minimum Payments, Due in Two Years	'	'	'	150	'
Operating Leases, Future Minimum Payments, Due in Three Years	'	'	'	150	'
Lessee Leasing Arrangements, Operating Leases, Term of Contract	'	'	'	'3 years	'
Stock Issued During Period, Shares, Share-based Compensation, Gross	'	'	'	4,000,000	'
Liability For Clinical Trial Material	'	'	'	500	'
Liability For Unissued Shares	'	'	'	22	'
Finite-Lived Intangible Assets, Net, Total	'	1,338	611	250	'
Asset Related To Transferred Clinical Trial Material	'	'	'	$500	'

8_SENIOR_CONVERTIBLE_DEBENTURE2

8% SENIOR CONVERTIBLE DEBENTURES (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument, Redemption [Line Items]	'	'
Stated Interest Rate	8.00%	8.00%
Long-term Debt, Gross	$339	$3,333
Current portion of 8% convertible promissory notes, net of debt discount	178	932
8% Senior Convertible Debenture Issuance One [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Issue Date	2-Oct-13	'
Maturity Date	2-Oct-14	'
Stated Interest Rate	8.00%	'
Conversion Terms	'Variable conversion price currently at $0.04	'
Long-term Debt, Gross	150	1,789
8% Senior Convertible Debenture Issuance Two [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Issue Date	6-Sep-13	'
Maturity Date	6-Sep-14	'
Stated Interest Rate	8.00%	'
Conversion Terms	'Variable conversion price, currently at $0.04	'
Long-term Debt, Gross	189	1,544
8% Senior Convertible Debenture Issuance One And Two [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Discount	-161	-2,401
8% Senior Convertible Debentures [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Current portion of 8% convertible promissory notes, net of debt discount	$178	$932

8_SENIOR_CONVERTIBLE_DEBENTURE3

8% SENIOR CONVERTIBLE DEBENTURES (Details Textual) (USD $)	3 Months Ended			75 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013	Mar. 31, 2014
Debt Instrument, Redemption [Line Items]	'		'	'
Debt Conversion, Converted Instrument, Amount	$4,784	[1]	'	'
Debt Discount Written Off, Convertible Promissory Notes	-1,740		0	-1,990
Senior Debt Obligations [Member]	'		'	'
Debt Instrument, Redemption [Line Items]	'		'	'
Debt Conversion, Converted Instrument, Rate	8.00%		'	'
8% Senior Convertible Debentures [Member]	'		'	'
Debt Instrument, Redemption [Line Items]	'		'	'
Debt Conversion, Converted Instrument, Amount	3,091		'	'
Debt Conversion, Converted Instrument, Principal Amount	2,995		'	'
Debt Conversion, Converted Instrument, Accrued Interest Amount	$96		'	'
Debt Conversion, Converted Instrument, Rate	8.00%		'	'
Debt Conversion, Converted Instrument, Shares Issued	77,405,866		'	'
[1]	The $4,784 was included with the debt discount in the statement of equity as result of the conversions of the convertible debt.

CONVERTIBLE_PROMISSORY_NOTES_D

CONVERTIBLE PROMISSORY NOTES (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Long-term Debt, Gross	$339	$3,333
Total convertible promissory notes	114	124
Convertible Promissory Notes Payable Issuance One [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	5-Jun-13	'
Debt Instrument, Maturity Date	2-Dec-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.02	'
Long-term Debt, Gross	20	20
Convertible Promissory Notes Payable Issuance Two [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	4-Nov-12	'
Debt Instrument, Maturity Date	3-May-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.01	'
Long-term Debt, Gross	0	10
Convertible Promissory Notes Payable Issuance Three [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	23-Aug-12	'
Debt Instrument, Maturity Date	19-Feb-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.015	'
Long-term Debt, Gross	50	50
Convertible Promissory Notes Payable Issuance Four [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-Nov-12	'
Debt Instrument, Interest Rate, Stated Percentage	0.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Refundable excess payment	'
Long-term Debt, Gross	1	1
Debt Instrument Maturity	'On Demand	'
Convertible Promissory Notes Payable Issuance Five [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	6-Jun-11	'
Debt Instrument, Maturity Date	6-Jun-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable at $0.04	'
Long-term Debt, Gross	10	10
Convertible Promissory Notes Payable Issuance Six [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	11-Apr-11	'
Debt Instrument, Maturity Date	11-Apr-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable at $0.04	'
Long-term Debt, Gross	25	25
Convertible Promissory Notes Payable Issuance Seven [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-May-11	'
Debt Instrument, Maturity Date	1-May-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.10	'
Long-term Debt, Gross	4	4
Convertible Promissory Notes Payable Issuance Eight [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-Apr-11	'
Debt Instrument, Maturity Date	1-Apr-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.10	'
Long-term Debt, Gross	$4	$4

CONVERTIBLE_PROMISSORY_NOTES_D1

CONVERTIBLE PROMISSORY NOTES (Details Textual) (USD $)	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 10, 2014	Mar. 31, 2014
Debt Instrument [Line Items]	'	'
Debt Instrument, Debt Default, Amount	'	$114
Board of Directors [Member]	'	'
Debt Instrument [Line Items]	'	'
Notes Payable, Related Parties	10	'
Accrued Interest Related Parties	1	'
Convertible Notes Payable [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Conversion, Converted Instrument, Shares Issued	1,095,759	'
Debt Instrument, Debt Default, Amount	'	$114

DEMAND_PROMISSORY_NOTE_Details

DEMAND PROMISSORY NOTE (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
In Thousands, unless otherwise specified			Dominion Capital, LLC. [Member]
Demand Promissory Notes [Line Items]	'	'	'
Demand Promissory Notes, Current	$500	$0	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%	12.00%
Debt Instrument, Maturity Date	'	'	14-Aug-14

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	0 Months Ended	3 Months Ended		1 Months Ended					0 Months Ended	3 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 10, 2014	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Jan. 10, 2014	Mar. 31, 2014	Jan. 10, 2014
				University of Massachusetts License [Member]	Maximum [Member]	Minimum [Member]	Sub-license Income [Member]	Sales Revenue, Net [Member]	MDx Purchase Agreement [Member]	PGI License Agreement [Member]	LPC Purchase Agreement [Member]
					University of Massachusetts License [Member]	University of Massachusetts License [Member]
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Lease Agreement Term	'	'one-year	'	'	'	'	'	'	'	'	'
Lease Agreement Initiation Period	'	'October 2013	'	'	'	'	'	'	'	'	'
Lease Rental Payments, Per Month	'	$7	'	'	'	'	'	'	'	'	'
Operating Leases, Rent Expense	'	21	8	'	'	'	'	'	'	'	'
License Costs	'	'	'	15	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Acquisitions	'	'	'	'	'	'	'	'	6,500,000	'	3,500,000
Concentration Risk, Percentage	'	'	'	'	'	'	10.00%	2.00%	'	'	'
Royalty Expense	'	'	'	'	500	125	'	'	'	'	'
Payment Of License Agreement Milestone Development Cost	4,000	'	'	'	'	'	'	'	'	'	'
Payment of License Agreement Milestone Development Cost upon Completion	1,000	'	'	'	'	'	'	'	'	'	'
Payment of License Agreement Milestone Development Cost upon Submission of Drug Application	3,000	'	'	'	'	'	'	'	'	'	'
Operating Leases, Future Minimum Payments Due, Total	'	'	'	'	'	'	'	'	'	450	'
Operating Leases, Future Minimum Payments Due, Next Twelve Months	'	'	'	'	'	'	'	'	'	150	'
Operating Leases, Future Minimum Payments, Due in Two Years	'	'	'	'	'	'	'	'	'	150	'
Operating Leases, Future Minimum Payments, Due in Three Years	'	'	'	'	'	'	'	'	'	$150	'
Lessee Leasing Arrangements, Operating Leases, Term of Contract	'	'	'	'	'	'	'	'	'	'3 years	'
Milestone Agreement Payment Description	'	'	'	'Milestones to be paid under the agreement are as follows: (i) $50 upon first human dosing, (ii) $75 upon initiation of first Phase 2 clinical trial, (iii) $100 upon initiation of first Phase 3 clinical trial, and (iv) $500 upon first product approval in the United States.	'	'	'	'	'	'	'

COMMON_STOCK_WARRANTS_Details

COMMON STOCK WARRANTS (Details) (Warrant [Member])	3 Months Ended
	Mar. 31, 2014
Warrant [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Annualized volatility	305.00%	[1]
Contractual term	'5 years
Risk-free investment rate	1.65%
Dividend yield	0.00%
[1]	The Company has three years of trading history that was utilized in computing the annualized volatility as of the date of issuance.

COMMON_STOCK_WARRANTS_Details_

COMMON STOCK WARRANTS (Details 1) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share Based Compensation Stock Options Activities [Line Items]	'	'
Option exercises (in shares)	-60,000,000	'
Weighted Average Exercise Price - Exercised	$0.06	'
Weighted Average Remaining Contractual Term-Balance	'4 years	'2 years 8 months 12 days
Exercised-Weighted Average Remaining Contractual Term	'2 years 8 months 12 days	'
Issued as a result of the above exercise	'4 years 10 months 24 days	'
Weighted Average Remaining Contractual Term-Balance	'4 years	'2 years 8 months 12 days
Warrant [Member]	'	'
Share Based Compensation Stock Options Activities [Line Items]	'	'
Number Of Warrants - Outstanding	69,553,306	84,553,306
Option exercises (in shares)	-60,000,000	'
Weighted Average Exercise Price - Balance	$0.10	0.06
Weighted Average Exercise Price - Exercised	$0.06	'
Weighted Average Exercise Price - Expired	$0.12	'
Issued as a result of the above exercise (in shars)	45,000,000	'

COMMON_STOCK_WARRANTS_Details_1

COMMON STOCK WARRANTS (Details Textual) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 07, 2014	Mar. 31, 2014	Dec. 31, 2013
Common Stock Warrant [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	'	60,000,000	'
Proceeds from Warrant Exercises	'	$3,600	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	'	$0.06	'
Warrant To Purchase Of Common Stock Exercised Description	'Pursuant to the offer to exercise dated February 13, 2014 as supplemented on March 6, 2014, the holders of outstanding warrants to purchase shares of common stock of the Company at a price of $0.06 (the Original Warrants) were offered the opportunity to exercise their Original Warrants and receive warrants (the New Warrants) to purchase three (3) shares of common stock of the Company for every four (4) Original Warrants exercised.	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	0.12	'
Common Stock Warrants Closing Price Per Share	'	$0.18	'
Warrants Issued To Purchase Common Stock, Shares	'	'	83,333,251
Fair Value Adjustment of Warrants	'	$3,867	'
Debenture And Warrant Transaction [Member]	'	'	'
Common Stock Warrant [Line Items]	'	'	'
Warrants Exercise Price, Per Share	'	$0.06	'
Warrants Exercise Price, Per Share, Based On Conditions	'	$0.00	'
New Warrants [Member] | Subsequent Event [Member]	'	'	'
Common Stock Warrant [Line Items]	'	'	'
Warrants Issued To Purchase Common Stock, Shares	45,000,000	'	'
Warrants Term	'5 years	'	'

COMMON_STOCK_PRIVATE_PLACEMENT1

COMMON STOCK PRIVATE PLACEMENTS (Details Textual) (LPC Purchase Agreement [Member], USD $)	1 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 07, 2014
LPC Purchase Agreement [Member]	'	'	'
Common Stock [Line Items]	'	'	'
Stock Purchase Agreement Description	'	'the per share purchase price will be the lesser of (1) the lowest sale price of common stock on the purchase date and (2) the average of the three lowest closing purchase prices during the 10 consecutive business days prior to the purchase date	'
Equity Financing Agreement Term	'30 months	'	'
Percentage of Weighted Average Price Determined Under Equity Financing Agreement	94.00%	'	'
Shares Obligated to Purchase Under Equity Financing Agreement	'	'	9,500,000
Shares Issuable upon Entering into Equity Financing Agreement	'	'	6,000,000
Shares Contingently Issuable Under Equity Financing Agreement	'	'	3,500,000
Shares Issued Under Equity Financing Agreement, Shares	'	'	4,000,000
Shares Issued Under Equity Financing Agreement, Value	$400,000	'	'
Value Of Shares Obligated to Purchase Under Equity Financing Agreement	'	'	20,000
Shares Issuable Upon Entering Into Equity Financing Agreement Treated As Deferred Funding Fee	'	'	6,000,000
Value Of Shares Issuable Upon Entering Into Equity Financing Agreement Treated As Deferred Funding Fee	'	'	516,000
Fees and Commissions	400,000	'	'
Deferred Funding Fees Offset Against Future Capital Raises	'	'	$116,000

STOCK_OPTION_PLANS_Details

STOCK OPTION PLANS (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation, Stock Options, Activity [Line Items]	'	'
Common Stock Option Outstanding - Options Exercised	-60,000,000	'
Weighted Average Exercise Price - Exercised	$0.06	'
Weighted Average Remaining Contractual Term-Balance	'4 years	'2 years 8 months 12 days
2008 Stock Plan [Member]	'	'
Share-based Compensation, Stock Options, Activity [Line Items]	'	'
Option Outstanding - Balance	6,941,288	'
Common Stock Option Outstanding - Options granted Employees	8,200,000	'
Common Stock Option Outstanding - Options granted Non-Employee	3,154,839	'
Common Stock Option Outstanding - Options Cancelled	0	'
Common Stock Option Outstanding - Options Exercised	0	'
Option Outstanding - Balance	18,296,127	6,941,288
Common Stock Option Outstanding - Options Vested as of March31, 2014	8,774,622	'
Weighted Average Exercise Price - Balance	$0.05	'
Weighted Average Exercise Price - Options granted Employee	$0.08	'
Weighted Average Exercise Price - Options granted Non-Employee	$0.08	'
Weighted Average Exercise Price - Options cancelled	$0	'
Weighted Average Exercise Price - Exercised	$0	'
Weighted Average Exercise Price - Balance	$0.07	0.05
Weighted Average Remaining Contractual Term-Balance	'9 years 6 months	'9 years
Outstanding Options Common Weighted Average Remaining Contractual Term - Employee	'10 years	'
Outstanding Options Common Weighted Average Remaining Contractual Term - Non-Employee	'10 years	'

STOCK_OPTION_PLANS_Details_1

STOCK OPTION PLANS (Details 1) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation, Stock Options, Activity [Line Items]	'	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Balance	'4 years	'2 years 8 months 12 days
Warrant [Member]	'	'
Share-based Compensation, Stock Options, Activity [Line Items]	'	'
Option Outstanding - Balance	69,553,306	84,553,306
Weighted Average Exercise Price - Balance	0.1	0.06
2012 Preferred Stock Plan [Member]	'	'
Share-based Compensation, Stock Options, Activity [Line Items]	'	'
Option Outstanding - Balance	2,287,500	'
Preferred Stock Option Outstanding - Preferred options cancelled	0	'
Preferred Stock Option Outstanding - Options granted Employees	200,000	'
Preferred Stock Option Outstanding - Options granted Non-Employee	0	'
Option Outstanding - Balance	2,487,500	2,287,500
Preferred options vested	1,482,161	'
Weighted Average Exercise Price - Balance	0.47	'
Weighted Average Exercise Price - Preferred options cancelled	0	'
Weighted Average Exercise Price - Options granted Employee	2.21	'
Weighted Average Exercise Price - Options granted Non-Employee	0	'
Weighted Average Exercise Price - Balance	0.61	0.47
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Preferred options cancelled	'0 years	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Options granted Employee	'9 years 9 months 18 days	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Options granted Non-Employee	'0 years	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Balance	'8 years 7 months 6 days	'8 years 6 months

STOCK_OPTION_PLANS_Details_2

STOCK OPTION PLANS (Details 2) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	$202	$508
Research and Development Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	78	282
General and Administrative Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	$124	$226

STOCK_OPTION_PLANS_Details_3

STOCK OPTION PLANS (Details 3) (Equity Option [Member])	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Equity Option [Member]	'	'
Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]	'	'
Weighted-average volatility	89.20%	108.00%
Weighted-average expected term	'5 years	'5 years
Expected dividends	0.00%	0.00%
Risk-free investment rate	1.65%	0.50%

STOCK_OPTION_PLANS_Details_Tex

STOCK OPTION PLANS (Details Textual) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jul. 31, 2012

Jul. 31, 2012

Jan. 31, 2014

Mar. 31, 2014

Jul. 15, 2012

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Maximum [Member]

Minimum [Member]

Stock Plan 2008 [Member]

Stock Plan 2008 [Member]

Preferred Stock Plan 2012 [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Time Based Shares [Member]

Performance Shares [Member]

Market Based Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

38,242,127

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

8,200,000

8,000,000

4,000,000

2,000,000

2,000,000

'

'

10,000,000

'

1,248,000

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total

$1,043

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'2 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'3 years

'2 years

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

'

$0.08

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares in Deficit

3,231,221

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

'25 percent upon grant and 1/36 per month thereafter

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

'

'

'

'

'

'

'

'

10,000,000

10,000,000

'

'

Preferred Stock Shares Designated Before Increase

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

Preferred Stock Shares Designated Increase

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

Preferred Stock Shares, Designated

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

3,000,000

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Details Textual) (USD $)	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 10, 2014
Related Party Transaction [Line Items]	'
Convertible Promissory Note converted, amount	$10
Convertible Promissory Note converted, shares	1,095,759
Convertible Promissory Note Accrued Interest Converted Amount	$1

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (Subsequent Event [Member], USD $)	1 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 29, 2014	1-May-14
	Memory Dx, LLC [Member]	Provista Diagnostics, Inc. [Member]
Subsequent Event [Line Items]	'	'
Asset Purchase Date Of Agreement	29-Apr-14	1-May-14
Purchase Agreement Amount	'	$20
Upfront Payment	50	'
Additional Payment To Be Made One	50	'
Additional Payment To Be Made Two	$50	'
Stock To Be Issued Upon Delivery Of Acquired Assets	1,500,000	'
Stock To Be Issued Upon License Agreement	6,500,000	'